Related Experiment Video
Updated: Mar 1, 2026
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Circulating Asprosin Concentrations and Body Weight Changes in Postmenopausal Women: Findings from the Women's Health
1Department of Epidemiology and Biostatistics, Joe C. Wen School of Population and Public Health, Division of Cardiovascular Science, Department of Medicine, School of Medicine; and the Center for Global Cardiometabolic Health and Nutrition, University of California, Irvine, CA, United States; Departments of Medicine and Surgery, The Warren Alpert Medical School, Brown University, Providence, RI, United States.
Background:
Weight changes after menopause contribute to cardiometabolic risk, yet hormonal determinants of long-term weight trajectories remain incompletely understood. Asprosin, a fasting-induced adipokine involved in hepatic gluconeogenesis and appetite regulation, has been associated with metabolic disease, although its prospective role in affecting weight change remains unknown.
Objectives:
This study aimed to examine whether plasma asprosin concentrations are directly and prospectively associated with changes in body weight and body composition among postmenopausal women.
Methods:
In a case-control study of 4020 postmenopausal women (1987 newly developed/incident diabetes cases and 2033 matched controls) nested within the Women's Health Initiative, we prospectively evaluated participants' baseline plasma concentrations of asprosin in relation to 3-y changes in weight, measures of central obesity, and the risk of major weight gain or loss (≥7% of baseline weight). Associations were examined overall and stratified by baseline body mass index (BMI) or whether the participant developed diabetes during follow-up. Dual-energy X-ray absorptiometry-derived fat and lean mass were available for a subset of participants (n = 178).
Results:
In the full cohort (n = 4020), baseline asprosin was not associated with 3-y weight change or changes in central adiposity. However, among matched controls with BMI <30 kg/m2, participants in the highest asprosin quartile gained 1.61 kg less than those in the lowest quartile [adjusted β: -1.61; 95% confidence interval (CI): -2.69, -0.52; P-trend < 0.01] and had lower odds of major weight gain (adjusted OR: 0.57; 95% CI: 0.37, 0.88; P-trend < 0.01) and higher odds of major weight loss (adjusted odds ratio: 1.83; 95% CI: 1.10, 3.05; P-trend = 0.02).
Conclusions:
In this prospective study of postmenopausal women followed for 3 y, baseline asprosin concentrations were associated with weight change in apparently healthy women without diabetes or obesity.
More Related Videos
03:05Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
Published on: November 21, 2025
14:26A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice
Published on: April 7, 2014
Related Concept Videos
01:28Menopause
01:22Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution